In this article, we will discuss Idecabtagene Vicleucel (Dosage Overview). So, let’s get started.
Idecabtagene Vicleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
For autologous use only. For intravenous use only.
Idecabtagene Vicleucel is provided as a single dose for infusion containing a suspension of chimeric antigen receptor (CAR)-positive T cells in one or more infusion bags. The recommended dose range is 300 to 460 x 106 CAR-positive T cells.